PNK-007 Treatment After Stem Cell Transplant Leads to Good Response Rates in Multiple Myeloma Patients, Early Trial Data Show
A single infusion of Celularity‘s PNK-007 — an investigational cell therapy derived from placental stem cells — is safe and leads to good response rates when administered to multiple myeloma patients a few days after autologous stem cell transplant (ASCT), preliminary results from a Phase 1 trial…